Skip to Main content Skip to Navigation
Journal articles

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

Mylene Annonay 1 Lisa Gauquelin 2, 1, 3 Romain Geiss 4 Mony Ung 5, 6 Laurence Cristol-Dalstein 7 Marie Ange Mouret-Reynier 8 Anthony Goncalves 9 Sophie Abadie-Lacourtoisie 10 Eric Francois 11 Christophe Perrin 12 Johan Le Fel 13 Veronique Lorgis 14 Veronique Servent 15 Lionel Uwer 16 Christelle Jouannaud 17 Marianne Leheurteur 13 Florence Joly 18 Loic Campion 10, 19 Coralie Courtinard 2, 3 Olivier Villacroux 10 Thierry Petit 20 Pierre Soubeyran 1 Catherine Terret 21 Carine Bellera 2, 3, 1 Etienne Brain 4 Suzette Delaloge 22
Abstract : BACKGROUND: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. METHODS: Women who initiated a treatment for HER2+ MBC between 2008 and 2016 in one of the 18 French comprehensive centers part of the ESME program were included. Objectives were the description of first-line treatment patterns, overall survival (OS), first-line progression-free survival (PFS), and prognostic factors among patients aged 70 years or more (70+), or less than 70 (<70). RESULTS: Of 4045 women diagnosed with an HER2+ MBC, 814 (20%) were 70+. Standard first-line treatment (chemotherapy combined with an anti-HER2 therapy) was prescribed in 65% of 70+ versus 89% of <70 patients (p < 0.01). Median OS was 49.2 (95% CI, 47.1-52.4), 35.3 (95% CI, 31.5-37.0) and 54.2 months (95% CI, 50.8-55.7) in the whole population, in patients 70+ and <70, respectively. Corresponding median PFS1 were 12.8 (95% CI, 12.3-13.3), 11.1 (95% CI, 10.0-12.3) and 13.2 months (95% CI, 12.7-13.9), respectively. In 70+ women, initiation of non-standard first-line treatment had an independent detrimental time-varying effect on both OS and PFS (HR on OS at 1 year: chemotherapy without anti-HER2 2.79 [95% CI: 2.05-3.79]; endocrine therapy and/or anti-HER2 1.96 [95% CI: 1.43-2.69]). CONCLUSIONS: In this large retrospective real-life database, older women with HER2+ MBC received standard first-line treatment less frequently than younger ones. This was independently associated with a worse outcome, but confounding factors and usual selection biases cannot be ruled out.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03468488
Contributor : Oskar Admin Connect in order to contact the contributor
Submitted on : Tuesday, December 7, 2021 - 10:43:54 AM
Last modification on : Wednesday, April 27, 2022 - 4:03:44 AM

File

BPH_TB_2021_Annonay.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Mylene Annonay, Lisa Gauquelin, Romain Geiss, Mony Ung, Laurence Cristol-Dalstein, et al.. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. Breast, Elsevier, 2021, 60, pp.138-146. ⟨10.1016/j.breast.2021.09.011⟩. ⟨hal-03468488⟩

Share

Metrics

Record views

55

Files downloads

7